New York, June 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Organ Transplant Immunosuppressant Drugs Global Market Report 2023" - https://www.reportlinker.com/p06466633/?utm_source=GNW
A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Mylan Laboratories Inc., Strides Pharma Global Pte Ltd., and Asahi Kasei Corporation.
The global organ transplant immunosuppressant drugs market is expected to grow from $5.03 billion in 2022 to $5.24 billion in 2023 at a compound annual growth rate (CAGR) of 3.08%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The organ transplant immunosuppressant drugs market is expected to reach $6.00 billion in 2027 at a CAGR of 3.44%.
The organ transplant immunosuppressant drugs market consists of sales of drugs such asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drug, and immunosuppressive agents.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The value of goods in this market includes related services sold by the creators of the goods.
Organ transplant immunosuppressant drugs are medications used to suppress the immune system of a transplant recipient to prevent rejection of the transplanted organ.
North America was the largest region in the organ transplant immunosuppressant drugs market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main classes of organ transplant immunosuppressant drugs are calcineurin inhibitors, antiproliferative agents, mtor inhibitor, steroids, and others.Calcineurin is an enzyme that plays a vital role in activating T-cells, immune cells that can attack transplanted organs.
Calcineurin inhibitors are immunosuppressant drugs that are used to prevent organ rejection in patients receiving organ transplants. It is used in transplant of heart, kidney, liver, lung, pancreas, and others and distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The increasing demand for organ transplantation will boost the organ transplant immunosuppressant drugs market.Organ transplantation is a surgical procedure in which a diseased or damaged organ in a person’s body is replaced with a healthy organ from a donor.
Organ transplantation is a life-saving procedure that replaces damaged or failed organs with healthy organs from a donor.Immunosuppressant drugs are essential to prevent the rejection of transplanted organs, which can lead to organ rejection.
The availability and effectiveness of immunosuppressant drugs are essential for the success of organ transplantation. For instance, in 2021, as per the data from the Global Observatory on Donation and Transplantation (GODT), an international organisation, 144,302 organs were transplanted annually in 2021, an 11.3% increase over 2020. Therefore, the increasing demand for organ transplantation will drive the organ transplant immunosuppressant drugs market forward.
Product innovation is a popular trend in the organ transplant immunosuppressant drugs market.Major companies operating in organ transplant immunosuppressant drugs focusing on developing innovative solutions, such as combination therapy, to sustain in the market.
Combination therapy involving two or more immunosuppressant drugs is becoming more common, as it can provide greater immunosuppression while reducing the risk of side effects. For instance, in July 2021, the U.S. Food and Drug Administration (FDA), a federal agency of the Department of Health and Human service, approved Prograf for use in combination with other immunosuppressant drugs for the prevention of organ rejection in patients receiving kidney, liver, or heart transplants. Prograf is an immunosuppressant, which was initially licensed to prevent organ rejection in patients undergoing liver transplants, later approved to prevent organ rejection in patients receiving kidney and heart transplants as well.
In September 2021, Sanofi S.A., a France-based pharmaceutical and healthcare company, acquired Kadmon Holdings for approximately $1.9 billion. Sanofi’s acquisition aims to expand its transplant business and pipeline by adding Kadmon’s immunosuppressant drug, Rezurock, which the US FDA recently approved for treating chronic graft-versus-host disease (cGVHD). Kadmon Holdings Inc. is a US-based biopharmaceutical firm that operates in organ transplant immunosuppressant drugs.
The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The organ transplant immunosuppressant drugs market research report is one of a series of new reports that provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with a organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: https://www.reportlinker.com/p06466633/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
